Astragaloside IV alleviates hypoxic pulmonary hypertension by inhibiting RELM-β to reduce PINK1/Parkin-mediated mitophagy in pulmonary artery smooth muscle cells (PASMCs).
Observational analysis shows aspartame IV improves pulmonary vascular remodelling in mice, highlighting its potential therapeutic effects.
Key Points
Astragaloside IV significantly reduces right ventricular systolic pressure and improves pulmonary vascular remodelling after hypoxia exposure.
Key evidence indicates that treatment improves hemodynamic parameters and attenuates right ventricular hypertrophy in a hypoxia-induced mouse model.
Assessment using various assays evaluated the impact of Astragaloside IV on PASMC proliferation, migration, and mitophagy through PINK1/Parkin pathways.
These findings suggest that targeting RELM-β and PINK1/Parkin channels could be beneficial in hypoxic pulmonary hypertension therapy.